Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Carmell Therapeutics ( (CTCX) ) just unveiled an announcement.
Carmell Therapeutics announced that on January 20, 2025, Kendra Bracken-Ferguson departed from her role as Chief Executive Officer by mutual agreement. Following her departure, she entered a separation agreement with the company, receiving $150,000 over six months. On January 24, 2025, Rajiv Shukla was appointed as the new CEO while retaining his role as Executive Chairman, marking a leadership transition within the company.
More about Carmell Therapeutics
YTD Price Performance: -36.23%
Average Trading Volume: 7,079,735
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $13.25M
Learn more about CTCX stock on TipRanks’ Stock Analysis page.